Anne-marie Ayral

Lille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Non-microglial downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease-related hallmarks.

Non-microglial downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease-related hallmarks.

Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026

Inflammatory stimulus enhances synaptic material uptake by adult APP microglia in a microfluidic neuron-microglia co-culture model.

Inflammatory stimulus enhances synaptic material uptake by adult APP microglia in a microfluidic neuron-microglia co-culture model.

Journal: Journal of neuroinflammation
Published: September 05, 2025

Calpain and caspase regulate Aβ peptide production via cleavage of KINDLIN2 encoded by the AD-associated gene FERMT2.

Calpain and caspase regulate Aβ peptide production via cleavage of KINDLIN2 encoded by the AD-associated gene FERMT2.

Journal: Neurobiology of aging
Published: July 04, 2024

PLCG2 downregulation impairs synaptic function and increases Alzheimer's disease hallmarks in neuronal cultures.

PLCG2 downregulation impairs synaptic function and increases Alzheimer's disease hallmarks in neuronal cultures.

Journal: Nature genetics
Published: May 17, 2024

High-Content Screening of Synaptic Density Modulators in Primary Neuronal Cultures.

High-Content Screening of Synaptic Density Modulators in Primary Neuronal Cultures.

Journal: Current protocols
Published: October 26, 2023

Voxel-Based Statistical Analysis of 3D Immunostained Tissue Imaging.

Voxel-Based Statistical Analysis of 3D Immunostained Tissue Imaging.

Journal: Frontiers in neuroscience
Published: April 29, 2018

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.

Journal: Acta neuropathologica
Published: October 19, 2016

ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease.

ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease.

Journal: EBioMedicine
Published: April 25, 2016
Showing 1-8 of 8

Last Updated: 09/26/2026